Dashboard
Manage Tickers

DYN Dyne Therapeutics, Inc.

Nasdaq dyne-tx.com


$ 16.31 $ -0.04 (-0.24 %)    

Friday, 17-Oct-2025 19:39:50 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 16.38
$ 16.22
$ 15.57 x 248
$ 17.05 x 5
$ 16.18 - $ 16.59
$ 6.36 - $ 35.68
1,727,217
na
2.33B
$ 1.14
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-28-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-27-2025 01-01-1970 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 03-05-2024 12-31-2023 10-K
8 10-30-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-02-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-02-2022 03-31-2022 10-Q
15 03-10-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-04-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

oppenheimer-downgrades-dyne-therapeutics-to-perform-maintains-price-target-to-13
Oppenheimer Downgrades Dyne Therapeutics t...
10/10/2025 17:47:16

Oppenheimer analyst Andreas Argyrides downgrades Dyne Therapeutics (NASDAQ:DYN) from Outperform to Perform and maintains the...

dyne-therapeutics-reveals-additional-one-year-clinical-data-demonstrating-functional-improvement-from-phase-12-achieve-trial-of-zeleciment-basivarsen--for-myotonic-dystrophy-type-1-meaningful-improvements-in-overall-disease-burden-reported-by-both-patients-and-physicians
Dyne Therapeutics Reveals Additional One-Y...
10/06/2025 22:03:51

WALTHAM, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on del...

raymond-james-upgrades-dyne-therapeutics-to-strong-buy-raises-price-target-to-35
Raymond James Upgrades Dyne Therapeutics t...
08/25/2025 14:47:29

Raymond James analyst Martin Auster upgrades Dyne Therapeutics (NASDAQ:DYN) from Outperform to Strong Buy and raises the pri...

dyne-therapeutics-shares-resume-trade
Dyne Therapeutics Shares Resume Trade
08/06/2025 15:25:55

dyne-therapeutics-shares-halted-on-circuit-breaker-to-the-upside-stock-now-up-244
Dyne Therapeutics Shares Halted On Circuit...
08/06/2025 15:22:25

oppenheimer-maintains-outperform-on-dyne-therapeutics-lowers-price-target-to-13
Oppenheimer Maintains Outperform on Dyne T...
08/06/2025 12:12:52

Oppenheimer analyst Andreas Argyrides maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target...

dyne-therapeutics-receives-fda-breakthrough-therapy-designation-for-dyne-251-in-duchenne-muscular-dystrophy-anticipates-bla-submission-in-early-2026
Dyne Therapeutics Receives FDA Breakthroug...
08/04/2025 11:34:42

- Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. acce...

stifel-maintains-buy-on-dyne-therapeutics-lowers-price-target-to-36
Stifel Maintains Buy on Dyne Therapeutics,...
07/31/2025 15:50:37

Stifel analyst Paul Matteis maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and lowers the price target from $66 to $36.

these-analysts-lower-their-forecasts-on-dyne-therapeutics-following-q2-loss
These Analysts Lower Their Forecasts On Dy...
07/29/2025 16:51:38

rbc-capital-maintains-outperform-on-dyne-therapeutics-lowers-price-target-to-23
RBC Capital Maintains Outperform on Dyne T...
07/29/2025 14:39:08

RBC Capital analyst Luca Issi maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $2...

raymond-james-reiterates-outperform-on-dyne-therapeutics-lowers-price-target-to-31
Raymond James Reiterates Outperform on Dyn...
07/29/2025 13:55:54

Raymond James analyst Martin Auster reiterates Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target ...

chardan-capital-maintains-buy-on-dyne-therapeutics-lowers-price-target-to-38
Chardan Capital Maintains Buy on Dyne Ther...
07/29/2025 10:35:42

Chardan Capital analyst Keay Nakae maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and lowers the price target from $50 ...

dyne-therapeutics-q2-eps-097-inline
Dyne Therapeutics Q2 EPS $(0.97), Inline
07/28/2025 20:29:44

Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.97) per share which met the analyst consensus estimate. This is...

jp-morgan-maintains-neutral-on-dyne-therapeutics-lowers-price-target-to-9
JP Morgan Maintains Neutral on Dyne Therap...
07/15/2025 16:19:37

JP Morgan analyst Tessa Romero maintains Dyne Therapeutics (NASDAQ:DYN) with a Neutral and lowers the price target from $10 ...

tesla-progress-software-dyne-therapeutics-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session
Tesla, Progress Software, Dyne Therapeutic...
07/01/2025 13:00:30

why-thumzup-media-shares-are-trading-higher-by-over-20-here-are-20-stocks-moving-premarket
Why Thumzup Media Shares Are Trading Highe...
07/01/2025 09:23:55

reported-earlier-dyne-therapeutics-prices-200m-public-offering-of-24242425-common-shares-at-825-each
Reported Earlier, Dyne Therapeutics Prices...
07/01/2025 06:46:46

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
06/30/2025 21:06:29

dyne-therapeutics-announces-proposed-public-offering-of-200m-common-stock
Dyne Therapeutics Announces Proposed Publi...
06/30/2025 20:09:20

Core News & Articles
Dyne Therapeutics Enters $275M Debt Financ...
06/30/2025 20:03:15

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION